|
Multiple sclerosis
Citations 461-470 of 475 total displayed.
|
Past content
(since Jan 2001):
|
- ARTICLES
Optimizing the association between disability and biological markers in MS
- N. F. Kalkers, E. Bergers, J. A. Castelijns, M. A. A. van Walderveen, J. C. J. Bot, H. J. Adèr, C. H. Polman, and F. Barkhof
Neurology 2001; 57: 1253-1258.
[Abstract]
[Full text]
[PDF]
- CLINICAL/SCIENTIFIC NOTES
Association of a tumor necrosis factor  polymorphism with MS susceptibility
- Brian G. Weinshenker, David D. Hebrink, Elizabeth Atkinson, and Orhun H. Kantarci
Neurology 2001; 57: 1341-1342.
[Full text]
[PDF]
- ARTICLES
Serum IFN neutralizing antibodies and neopterin levels in a cross-section of MS patients
- S. D. Cook, J. R. Quinless, A. Jotkowitz, and P. Beaton
Neurology 2001; 57: 1080-1084.
[Abstract]
[Full text]
[PDF]
- BRIEF COMMUNICATIONS
Satellite potentials on EMG: Neurophysiologic evidence of axonal transection in MS?
- G. Antonini, S. Morino, F. Giubilei, A. Paolillo, V. Ceschin, F. Gragnani, E. Bucci, and C. Pozzilli
Neurology 2001; 57: 1126-1128.
[Abstract]
[Full text]
[PDF]
- BRIEF COMMUNICATIONS
TNF production by CD4+ T cells predicts long-term increase in lesion load on MRI in MS
- J. Killestein, N. F. Kalkers, J. F. Meilof, F. Barkhof, R. A. W. van Lier, and C. H. Polman
Neurology 2001; 57: 1129-1131.
[Abstract]
[Full text]
[PDF]
- BRIEF COMMUNICATIONS
Downregulation of transforming growth factor-ß1 in interferon-ß1a-treated MS patients
- J. D. Lünemann, O. Aktas, P. Gniadek, R. Zschenderlein, and F. Zipp
Neurology 2001; 57: 1132-1134.
[Abstract]
[Full text]
[PDF]
- ARTICLES
Fatigue is not associated with raised inflammatory markers in multiple sclerosis
- Gavin Giovannoni, Alan J. Thompson, David H. Miller, and Edward J. Thompson
Neurology 2001; 57: 676-681.
[Abstract]
[Full text]
[PDF]
- ARTICLES
Differing effects of IFNß vs IFN in MS: Gene expression in cultured astrocytes
- Jun-ichi Satoh and Yasuo Kuroda
Neurology 2001; 57: 681-685.
[Abstract]
[Full text]
[PDF]
- BRIEF COMMUNICATIONS
14-3-3 protein in the CSF as prognostic marker in early multiple sclerosis
- A. Martínez–Yélamos, A. Saiz, R. Sanchez–Valle, V. Casado, J. M. Ramón, F. Graus, and T. Arbizu
Neurology 2001; 57: 722-724.
[Abstract]
[Full text]
[PDF]
- BRIEF COMMUNICATIONS
Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes"
- M. Filippi, M. Rovaris, M. A. Rocca, M. P. Sormani, J. S. Wolinsky, and G. Comi
Neurology 2001; 57: 731-733.
[Abstract]
[Full text]
[PDF]
|
|
